



12th June 2024

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East, Mumbai 400 050

Minutes of the 68th Annual General Meeting of the Company held on 14th May 2024

Dear Sirs,

Please find enclosed a copy of the minutes of the 68th Annual General Meeting of the Company held on 14th May 2024 through Video Conferencing / Other Audio-Visual Means facility. The same is also being uploaded on the Company's website.

Please take the above information on record.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

Radhika Shah
Company Secretary & Compliance Officer
Membership No.: 19308

SANOFI INDIA LIMITED

MINUTES OF THE SIXTY-EIGHTH ANNUAL GENERAL MEETING OF THE MEMBERS OF SANOFI INDIA LIMITED HELD ON TUESDAY, 14TH MAY 2024 FROM 3:30 PM TO 5:00 PM THROUGH VIDEO CONFERENCING / OTHER AUDIO-VISUAL MEANS ('VC / OAVM') FACILITY AT THE REGISTERED OFFICE - SANOFI HOUSE, 117-B, SAKI VIHAR ROAD, POWAI, MUMBAI (DEEMED VENUE OF THE MEETING)

Present through Video Conferencing / Other audio-visual means (VC / OAVM) facility:

Directors & Company Secretary

1. Mr. Aditya Narayan (Chairman and Independent Director) attended the meeting from Sanofi, Head Office – Mumbai
2. Ms. Usha Thorat (Independent Director and Chairperson of Nomination and Remuneration Committee, CSR Committee, and Risk Management Committee) attended the meeting from Sanofi, Head Office – Mumbai
3. Mr. Rahul Bhatnagar (Independent Director and Chairperson of the Audit Committee and Stakeholder Relationship Committee) attended the meeting from Sanofi, Head Office – Mumbai
4. Mr. Rodolfo Hrosz (Managing Director) attended the meeting from Sanofi, Head Office – Mumbai
5. Mr. Vaibhav Karandikar (Non-Executive Director) attended the meeting from Sanofi, Head Office – Mumbai
6. Mr. Rachid Ayari (Whole-time Director and Chief Financial Officer) attended the meeting from Sanofi, Head Office – Mumbai
7. Ms. Renee Amonkar (Whole-time Director and Site Director, Goa) attended the meeting from Goa.
8. Ms. Radhika Shah (Head of Legal and Company Secretary) attended the meeting from Sanofi, Head Office – Mumbai

Invitees

1. Mr. Eric Mansion (General Manager, Pharma Business, MCO, South-East Asia & India) attended the meeting from France.

Members' Attendance & Quorum through VC facility

- Total 57 members including authorized representatives were present at the meeting through VC/ OAVM.
- Mr. Rachid Ayari and Ms. Radhika Shah represented Hoechst GmbH and Sanofi SA, respectively holding cumulatively 1,39,09,587 shares.

The Chairman declared the meeting as validly convened on the basis of advice from the Company Secretary that the requirement of quorum as per the Companies Act, 2013 read with the circulars issued by the Ministry of Corporate Affairs were fulfilled.

Auditors present through VC

- Mr. Arun Ramdas, Partner of M/s. Price Waterhouse & Co Chartered Accountants LLP (Statutory Auditors) attended the meeting from Mumbai.
- Mr. Omkar Dindorkar, Partner of M/s. Makarand M. Joshi & Associates & Co., (Secretarial Auditors) attended the meeting from Mumbai.
- Mr. Sukrut Mehta, Partner of M/s. Kirit Mehta & Co., (Cost Auditors) attended the meeting from Mumbai.

Statutory Registers

The Statutory Registers as per requirement of the Companies Act, 2013 were open for inspection through electronic mode.

Details on VC / OAVM and e-voting

Ms. Radhika Shah, Company Secretary, welcomed the members to the Company's 68th Annual General Meeting. She stated that the meeting was being held through Video Conferencing / Other Audio-Visual Means (VC / OAVM) in accordance with the circulars issued by Ministry of Corporate Affairs, applicable provisions of the Companies Act 2013 and SEBI Listing Obligations and Disclosure Regulations (SEBI Listing Regulations).

She further informed the Members that the proceedings of the meeting were being webcast live for all the shareholders as per the details provided in the notice to the Annual General Meeting. In accordance with the provisions of the Companies Act and SEBI Listing Regulations, Members had been provided with the facility to exercise their right to vote by electronic means both through remote e-voting facility and e-voting at the Annual General Meeting. Remote e-voting facility was made available

to all the Members holding shares as on the cut-off date of 7th May 2024, for the period commencing from 9:00 AM IST on 11th May 2024 till 5:00 PM IST on 13th May 2024.

She further informed the members that the Scrutinizers had been asked to finalize their report on results of remote e-voting results and the e-voting during this AGM and submit their report within 48 hours. She informed that the results of the voting would be announced by posting it on the Company's website and sending it to the Stock Exchanges.

Chairman of the meeting

Mr. Aditya Narayan, Chairman of the Company took the chair and introduced himself. He then announced that the requisite quorum being present, the meeting was called to order.

Introduction of Directors

The Chairman introduced the Directors present at the meeting. He apprised the members that Mr. Vaibhav Karandikar, who after transitioning to another role within the Sanofi group, had ceased to be the Whole-time Director and Chief Financial Officer of the Company with effect from 30th November 2023. However, he informed that Mr. Karandikar continued to be a Non-Executive Director on the Board, effective from 1st December 2023.

The Chairman also informed the members that Mr. Mathew Cherian, Whole-Time Director & Head of Industrial Affairs and Mr. Marc-Antoine Lucchini, Non-Executive Director had stepped down from the Company's Board on 26th September 2023 and 28th March 2024, respectively. He then on behalf of the Board, placed on record deep appreciation for their valuable contribution during their tenure on the Board.

Notice convening meeting

The Notice convening the meeting was taken as read.

Statutory Auditor's Report and Secretarial Audit Report

The Chairman informed the members that the Auditor's Report on the Annual Accounts for the financial year 2023 was taken as read.

He further stated that, Mr. Arun Ramdas, Partner of Price Waterhouse Coopers, Chartered Accountants, the Statutory Auditors of the Company was present at the

meeting to answer any questions on Auditors' Report. He further mentioned that the Auditors Report issued did not contain any qualifications, observations, or comments.

The Board had appointed M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, to conduct the Secretarial Audit of your Company for the year ended 31st December 2023. The comments made by the Secretarial Auditors are self-explanatory, and their report was included in the Annual Report.

Chairman's Speech

The Chairman opened the meeting by expressing his expectation that all attendees had already reviewed the 2023 Integrated Annual Report, as well as the operational and financial performance from the past year. He proposed to keep his remarks brief, focusing on key points.

He emphasized the Company's longstanding commitment to providing innovative and affordable medicines in India, spanning over six decades. The Company's efforts extend across the health spectrum, from disease prevention to treatment, patient support, and capacity-building, all conducted with the highest standards of corporate governance.

The Chairman then provided an overview of the business environment. Despite global economic challenges and geopolitical volatility, India maintained robust economic growth in 2023, with a real GDP increase of over 7%. The government's initiatives such as Ayushman Bharat and Make in India, among others, demonstrate a strong commitment to healthcare and domestic manufacturing. In response, the Company adopted an "India for India" strategy to meet growing healthcare demands.

He proceeded to highlight key developments for the year 2023, beginning with the demerger of the Consumer Healthcare Business. Approved by the Board in May 2023 and by shareholders in December 2023, the demerger petition was admitted by the National Company Law Tribunal, Mumbai, on 16th January 2024. Following a hearing, the Tribunal sanctioned the Scheme on 7th May 2024, paving the way for the listing of the new separate company, Sanofi Consumer Healthcare Limited. This move is expected to unlock shareholder value and drive rapid growth.

Next, he discussed the expansion of diabetes treatment, noting the Company's dedication to providing high-quality medicines and services in response to the increasing prevalence of diabetes in India. He highlighted the introduction of Soliqua™ and the Company's efforts to strengthen its oral portfolio.

Further, he mentioned partnerships with Emcure Pharmaceuticals Limited and Cipla Limited to expand the reach of established brands and enhance operational efficiency. He also emphasized the Company's focus on digital transformation and sustainability initiatives, including efforts to achieve carbon neutrality by 2030 and promote diversity, equity, and inclusion.

The Chairman concluded with a review of the Company's performance in 2023, noting a 2.8% growth in revenue despite challenges such as negative price rationalization. He informed that the Board for the financial year, had approved dividend a total dividend of Rs. 167 per share. An interim dividend of Rs 50 per share had already been paid to shareholders in March 2024, and the balance of Rs. 117 per share would be paid soon after approval of accounts at the meeting.

With these remarks, the Chairman concluded his opening statement and transitioned to the proposed resolutions.

The meeting proceeded with discussions on the proposed resolutions and other agenda items.

Resolutions passed at the meeting

The following resolutions were proposed at the meeting:

Ordinary business:

- 1. Ordinary Resolution for the adoption of the Annual Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended December 31, 2023, including the Balance Sheet as on December 31, 2023, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of Board of Directors and Auditors thereon.**

"RESOLVED THAT the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended December 31, 2023, including Balance Sheet as at December 31, 2023, Statement of the Profit and Loss and Cash Flow Statement for the year ended on that date and the Reports of the Board of Directors and Auditors thereon, be and are hereby approved and adopted."

2. Ordinary Resolution

- a. For confirmation of the payment of Interim Dividend of Rs. 50 per equity share of Rs. 10 each for the Financial Year ended December 31, 2023.**

- b. For declaration of a final dividend of Rs. 117 per equity share of Rs. 10 each for the Financial Year ended December 31, 2023.**

"RESOLVED THAT the Interim dividend of Rs. 50/- per equity share of the face value of Rs. 10/- each for the Financial Year ended December 31, 2023, which was paid to the Shareholders on March 20, 2024, be and is hereby noted and confirmed.

RESOLVED FURTHER THAT a final dividend of Rs. 117/- per equity share of the face value of Rs. 10/- each, for the year ended December 31, 2023, be paid to:

- those Members whose names appear on the Register of Members of the Company on May 3, 2024; and

- those whose names appear as beneficial owners as at the close of business on May 3, 2024, as per details to be furnished by the National Securities Depository Limited and Central Depository Services (India) Limited."

3. Ordinary Resolution for re-appointment of Mr. Vaibhav Karandikar (DIN: 09049375), who retires by rotation and being eligible, offers himself for re-appointment.

"RESOLVED THAT Mr. Vaibhav Karandikar (DIN: 09049375) who retires by rotation and being eligible for re-appointment, be and is hereby appointed as Director of the Company."

4. Ordinary Resolution for re-appointment of Mr. Rodolfo Hrosz (DIN: 09609832), who retires by rotation and being eligible, offers himself for re-appointment.

"RESOLVED THAT Mr. Rodolfo Hrosz (DIN: 09609832) who retires by rotation and being eligible for re-appointment, be and is hereby appointed as Director of the Company."

Special business:

5. Ordinary Resolution for Ratification of remuneration to Cost Auditors

“RESOLVED THAT pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or reenactment thereof for the time being in force), the remuneration payable to M/s. Kirit Mehta & Co., Cost Accountants (Firm Registration No. 000353), appointed by the Board of Directors on the recommendation of the Audit Committee, as Cost Auditors of the Company to conduct the audit of the cost records of the Company for the Financial Year ending December 31, 2024, amounting to Rs. 460,000 (Rupees Four Lakhs Sixty Thousand Only) plus applicable taxes and reimbursement of out of pocket expenses incurred in connection with the aforesaid audit, be and is hereby ratified.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorised to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

The Chairman informed the members that since this meeting was being held through VC / OAVM facility and resolutions were put to vote only through e-voting, the practice of proposing and seconding of resolutions was not being followed.

Shareholder queries received in advance

The Chairman informed the members that as part of AGM Notice, the shareholders who had queries or were seeking clarifications on the proposals or on the Annual Report were requested to send their queries on e-mail on or before 5:00 pm on Tuesday, May 7, 2024, hence only those queries which were received in advance were duly noted and answered. The Company had received queries on various topics from shareholders.

The Chairman answered queries about the future roadmap for the Company, initiatives for growth, R&D initiatives, steps for improving margins and the status of the Demerger of the CHC Business of the Company.

Speakers at the Annual General Meeting

The Chairman informed that the Members who had wished to speak at the meeting were requested to register themselves as a speaker by sending an e-mail to the Company on or before 5:00 pm on Tuesday, May 7, 2024, and that the Company had received overwhelming response from shareholders to speak at this meeting.

Following Speaker shareholders participated in the sequence they had pre-registered with the Company as Speakers to ask questions / give comments on the Agenda Items as set out in the AGM Notice:

Mr. Kaushik Sahukar
Mr. Rishikesh Chopra
Mr. Anandu Vithal Nayak
Mr. Dinesh Bhatia
Mr. Ashish Shankar Bansal
Mr. Anil B. Mehta
Mr. Bharat Shah
Mrs. Minal Bang
Mr. Hiranand Kotwani
Mrs. Celestine Mascarenhas
Mr. Yusuf Rangwala
Mrs. Lekha Shah
Mr. Bimal Kumar Agarwal

Some of the key remarks and suggestions made by the speaker shareholders at the meeting were as follows:

- Recognized the efforts of the Management and acknowledged good performance and progress of the Company
- Appreciated the Board on the dividends for the year 2023
- Requested the Board to consider Bonus issue / stock split of shares
- Inquired about Company's Sales growth, litigations, new product launches, Company's future plans, etc.

All the suggestions given by the speakers were noted and Chairman thanked the Members for their questions and suggestions.

He then requested Mr. Rodolfo Hrosz, Managing Director and Mr. Rachid Ayari, Whole-time Director and Chief Financial Officer for their response to the questions and comments on the suggestions made by the speaker shareholders.

Mr. Rodolfo Hrosz then thanked the shareholders and began by expressing gratitude and greeted the attendees. He acknowledged the questions posed during the meeting and proceeded to affirm that he would address the commercial and strategic inquiries, while Rachid would handle the financial aspects.

He started with the statement by shareholder Kaushik Sahukar regarding the dynamic and competitive Indian market, it was agreed upon that India presented a dynamic

and competitive market, aligning with the company's perspective. The long-term strategy, as raised by Mr. Rishikesh Chopra, was centered around the "India for India" plan, which was unveiled at the end of 2022.

The plan's first pillar focused on diabetes, a market with significant untapped potential. Despite a high prevalence of diabetes, insulin utilization remained low. The company aimed to capitalize on this through leading brands Lentus and Toujeo, which dominated the basal insulin segment. Additionally, entry into the premix insulin segment with Soliqua addressed another critical area of need. Transitioning towards a more customer-centric go-to-market approach was also emphasized.

The second pillar involves the demerger of the consumer healthcare (CHC) business to enhance its focus and maximize growth opportunities. This move will provide dedicated leadership and access to a global portfolio for innovation. The managing director reaffirmed their role post-demerger, ensuring continuity in leading Sanofi India Limited.

The third pillar emphasizes local innovation and localization, with progress made in launching new products and localizing production. Lastly, the fourth pillar focuses on go-to-market modernization and partnerships to expand reach and reduce costs. Recent partnerships with Cipla and Emcure aim to strengthen distribution and drive growth in specific segments.

In summary, the company aims to unlock growth potential in the Indian market through a comprehensive strategy focusing on diabetes, consumer healthcare, innovation, and partnerships.

He then requested Mr. Rachid Ayari, Whole-time Director and Chief Financial Officer to respond on the rest of the questions raised by the shareholders in relation to the financial aspects and the Results of the Company for the year ended 31st December 2023.

Mr. Rachid Ayari thanked everyone for their presence and the questions raised. He then elaborated on the financial situation for 2023, noting that despite a 24% price decrease for Lantus due to NLEM and a divestment in 2022, Sanofi India achieved a 13% growth in profit before exceptional items, thanks to a dedicated team and effective leadership.

He further informed that regarding Consumer Healthcare (CHC), the Company was auditing and disclosing numbers as one segment. The split would occur in Q2 2024. Meanwhile, CHC represented roughly 30% of net sales and 37-39% of total operating profit. This would be confirmed by external auditors soon.

Inventory growth in 2023 showed an increase due to stockpiling and changes in distribution centers, mainly for imported products, to mitigate business impact in 2024. Early 2024 saw a decrease in inventory and a rebuilding of cash.

The Goa site's capacity utilization was at 80%, with three teams working six days a week, providing competitive costs compared to other Sanofi sites outside India.

On the National Pharmaceutical Pricing Authorities, the provision made in the books was deemed adequate, audited, and justified, with returns and income tax deductibility claimed as per rules.

The Board considered dividend and bonus share splits periodically, with further discussion planned for the next meeting. Miscellaneous income mainly stemmed from the divestment of Trental and certain accrual reversals in 2023. Additional tax-related questions would be addressed later.

The Chairman thanked Mr. Rodolfo Hrosz and Mr. Rachid Ayari for their comments and requested Ms. Radhika Shah, Head of Legal and Company Secretary, to answer queries regarding the appointed date of the Scheme, the share exchange ratio, and the record date for the allotment of shares of Sanofi Consumer Healthcare India Limited.

Ms. Radhika Shah informed that initially, an application to NCLT resulted in the court granting April 1, 2023, as the appointed date, which was the date before incorporation of the subsidiary. This discrepancy was corrected to June 1, 2023, through successful application and approval of the rectification order. Regarding the demerger ratio, it was clarified that the scheme establishes a 1:1 ratio, implying that each shareholder of Sanofi India Limited holding one share will receive one share of Sanofi Consumer Healthcare India Limited. The specific record date or book closure for this transaction will be determined by the Board of Directors in the following months, with updates provided through intimations to the stock exchanges.

The Chairman then thanked Ms. Radhika Shah and expressed gratitude for the comprehensive discussion, noting that most of the key questions had been addressed. Any remaining queries were acknowledged, and shareholders were informed to reach out to the Company Secretary via email for further clarification. Appreciation was extended to all for their support during a transformative year marked by significant changes in strategy, including the demerger. The Chairman thanked shareholders for their trust and pledged continued support as the Company moved forward with its outlined strategy. Recognition was also given to employees for their dedication during a challenging year of transformation. Gratitude was

expressed to all stakeholders, including government agencies, for their ongoing support.

As the meeting concluded, the Chairman extended well wishes for the upcoming year and urged shareholders to cast their votes on resolutions using the e-voting system.

Finally, with no further matters to discuss, the Chairman concluded the meeting, expressing hope that all attendees were satisfied with its outcomes.

Vote of thanks

The meeting concluded at 5:00 p.m. with a vote of thanks.

Scrutinizers Report

A brief summary of Scrutinizer's Report on the remote e-voting and the e-voting conducted at the Annual General Meeting and the result of the voting thereon is enclosed as **Annexure-1**.

Date:

Place: Gurugram

Sd/-
CHAIRMAN

CERTIFIED TRUE COPY

Radhika Shah
Head of Legal and Company Secretary

Summary of Scrutinizer's Report

1. Cut-off date

The Voting rights were reckoned as on, 7th May 2024, being the cut-off date for the purpose of deciding the entitlements of members at the remote e-voting and e-voting during the AGM

2. E-voting Process

Agency: The Company had appointed NSDL as the agency for providing the remote e-Voting platform.

Remote e-voting process done by the shareholders of the Company pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014; and

Electronic Voting at the AGM under the provisions of Section 109 of the Companies Act, 2013 read with Rule 21 of the Companies (Management and Administration) Rules, 2014 at the 68th AGM held on Tuesday, 14th May 2024.

- 3.** The Scrutinizers mentioned in their report that during the scrutinizer process, it was noticed that a discrepancy existed in the allocation of voting rights for a subset of shareholders. Upon examination, it was determined that an error had occurred during the upload of the shareholders' list as of the cutoff date by the Registrar and Transfer Agent's (RTA). As a result, 1,130 shareholders were unable to exercise their voting rights, while 780 shareholders received excess voting rights compared to their shareholding. This discrepancy affected approximately 0.09% of the total shareholding.

It was clarified that for those shareholders who received excess voting rights, they had only considered their rightful shareholding as of the cutoff date, i.e., 7th May 2024, and had not counted the excess votes. It was further highlighted that despite the irregularities all resolutions have received the required majority as per legal regulations, notwithstanding the discrepancies in the allocation of voting rights.

4. Results

Date of AGM	May 14, 2024
Total number of shareholders on record date (i.e., May 7, 2024, as on)	64,475
No. of shareholders present in the meeting either in person or through proxy:	
Promoter and Promoter group	NA
Public	NA
No. of shareholders attended the meeting through Video Conferencing:	
Promoter and Promoter group	02
Public	55

The Consolidated Results with respect to the item on the agenda as set out in the Notice of the AGM dated 23rd February 2024 is as given below. Based on the aforesaid results, five (5) Ordinary resolutions as contained in the Notice of the AGM dated were passed with the requisite majority.

Resolution Item No. 1 - Ordinary Resolution:

To receive, consider and adopt the Annual Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended December 31, 2023 including the Balance Sheet as on December 31, 2023, the Statement of Profit and Loss and the Cash Flow Statement for the Financial Year ended on that date and Reports of Board of Directors and Auditors thereon.

Sr. No	Promoter/ Public	Mode of Voting	Total No. of Shares Held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes - in favour	No. of Votes - against	% of Votes in favour on votes polled	% of Votes against on votes polled
			[1]	[2]	[3]=[2]/(1)*100	[4]	[5]	[6]=[4]/(2)*100	[7]=[5]/(2)*100
1	Promoter and Promoter Group	Remote E-Voting	1,39,09,587	1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
2	Public - Institutional holders	Remote E-Voting	62,93,824	59,02,730	93.7861	59,02,730	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		59,02,730	93.7861	59,02,730	0	100.0000	0.0000
3	Public-Non-Institutional	Remote E-Voting	28,27,211	4,25,080	15.0353	4,25,077	3	99.9993	0.0007
		Poll		61	0.0022	61	0	0.0000	0.0000
		Total		4,25,141	15.0375	4,25,138	3	99.9993	0.0007
Total			2,30,30,622	2,02,37,458	87.8720	2,02,37,455	3	100.0000	0.0000

Resolution Item No. 2 - Ordinary Resolution:

A. To confirm the payment of Interim Dividend of ₹ 50 per equity share of ₹ 10 each for the Financial Year ended December 31, 2023.

B. To declare a final dividend of ₹ 117 per equity share of ₹ 10 each for the Financial Year ended December 31, 2023

Sr. No	Promoter/ Public	Mode of Voting	Total No. of Shares Held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes - in favour	No. of Votes - against	% of Votes in favour on votes polled	% of Votes against on votes polled
			[1]	[2]	[3]=[2]/(1)*100	[4]	[5]	[6]=[4]/(2) *100	[7]=[5]/(2) *100
1	Promoter and Promoter Group	Remote E-Voting	1,39,09,587	1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
2	Public - Institutional holders	Remote E-Voting	62,93,824	59,13,784	93.9617	59,13,784	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		59,13,784	93.9617	59,13,784	0	100.0000	0.0000
3	Public-Non- Institutional	Remote E-Voting	28,27,211	4,25,131	15.0371	4,25,047	84	99.9802	0.0198
		Poll		61	0.0000	61	0	0.0000	0.0000
		Total		4,25,192	15.0393	4,25,108	84	99.9802	0.0198
Total			2,30,30,622	2,02,48,563	87.9202	2,02,48,479	84	99.9996	0.0004

Resolution Item No. 3 - Ordinary Resolution:

To re-appoint Mr. Vaibhav Karandikar (DIN: 09049375), who retires by rotation and being eligible, offers himself for re-appointment.

Sr. No	Promoter/ Public	Mode of Voting	Total No. of Shares Held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes - in favour	No. of Votes - against	% of Votes in favour on votes polled	% of Votes against on votes polled
			[1]	[2]	[3]=[2]/(1)*100	[4]	[5]	[6]=[4]/(2) *100	[7]=[5]/(2) *100
1	Promoter and Promoter Group	Remote E-Voting	1,39,09,587	1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
2	Public - Institutional holders	Remote E-Voting	62,93,824	59,13,387	93.9554	56,43,567	2,69,820	95.4371	4.5629
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		59,13,387	93.9554	56,43,567	2,69,820	95.4371	4.5629
3	Public-Non- Institutional	Remote E-Voting	28,27,211	4,25,131	15.0371	4,24,845	286	99.9327	0.0673
		Poll		61	0.0022	61	0	100.0000	0.0000
		Total		4,25,192	15.0393	4,24,906	286	99.9327	0.0673
Total			2,30,30,622	2,02,48,166	87.9185	1,99,78,060	2,70,106	98.6660	1.3340

Resolution Item No. 4 - Ordinary Resolution:

To re-appoint Mr. Rodolfo Hrosz (DIN: 09609832), who retires by rotation and being eligible, offers himself for re-appointment.

Sr. No	Promoter/ Public	Mode of Voting	Total No. of Shares Held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes - in favour	No. of Votes - against	% of Votes in favour on votes polled	% of Votes against on votes polled
			[1]	[2]	[3]=[2]/(1)*100	[4]	[5]	[6]=[4]/(2) *100	[7]=[5]/(2) *100
1	Promoter and Promoter Group	Remote E-Voting	1,39,09,587	1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
2	Public - Institutional holders	Remote E-Voting	62,93,824	59,13,387	93.9554	58,78,576	34,811	99.4113	0.5887
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		59,13,387	93.9554	58,78,576	34,811	99.4113	0.5887
3	Public-Non- Institutional	Remote E-Voting	28,27,211	4,25,131	15.0371	4,24,987	144	99.9661	0.0339
		Poll		61	0.0000	61	0	100.0000	0.0000
		Total		4,25,192	15.0393	4,25,048	144	99.9661	0.0339
Total			2,30,30,622	2,02,48,166	87.9185	2,02,13,211	34,955	99.8274	0.1726

Resolution Item No. 5 - Ordinary Resolution:

Ratification of remuneration to Cost Auditors.

Sr. No	Promoter/ Public	Mode of Voting	Total No. of Shares Held	No. of votes polled	% of Votes Polled on outstanding shares	No. of Votes - in favour	No. of Votes - against	% of Votes in favour on votes polled	% of Votes against on votes polled
			[1]	[2]	[3]=[2]/(1)*100	[4]	[5]	[6]=[4]/(2) *100	[7]=[5]/(2) *100
1	Promoter and Promoter Group	Remote E-Voting	1,39,09,587	1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		1,39,09,587	100.0000	1,39,09,587	0	100.0000	0.0000
2	Public - Institutional holders	Remote E-Voting	62,93,824	59,13,387	93.9554	59,13,387	0	100.0000	0.0000
		Poll		0	0.0000	0	0	0.0000	0.0000
		Total		59,13,387	93.9554	59,13,387	0	100.0000	0.0000
3	Public-Non- Institutional	Remote E-Voting	28,27,211	4,25,131	15.0371	4,24,961	170	99.9600	0.0400
		Poll		61	0.0022	61	0	100.0000	0.0000
		Total		4,25,192	15.0393	4,25,022	170	99.9600	0.0400
Total			2,30,30,622	2,02,48,166	87.9185	2,02,47,996	170	99.9992	0.0008

Notes:

- Voting rights on the shares transferred to 'Unclaimed Suspense Account' and those shares transferred to the 'Investor Education and Protection Fund' are frozen.
- The votes cast does not include invalid votes & abstained votes.
- All the aforesaid resolutions were passed with requisite majority.